---
title: "TSPAN32 boosts CAR‑T efficacy by assembling the IL‑2 receptor and enhancing signaling"
id: "british-journal-of-cancer-2-tspan32-enhances-car-t-cell-potency-by-assembling-il-2-receptor-complex-and"
canonical_url: "https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-tspan32-enhances-car-t-cell-potency-by-assembling-il-2-receptor-complex-and"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "British Journal of Cancer"
source_url: "https://www.nature.com/articles/s41416-026-03592-x"
published_at: "2026-09-19T12:00:00.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# TSPAN32 boosts CAR‑T efficacy by assembling the IL‑2 receptor and enhancing signaling
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/british-journal-of-cancer-2-tspan32-enhances-car-t-cell-potency-by-assembling-il-2-receptor-complex-and
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** British Journal of Cancer
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41416-026-03592-x)
- **Published At:** 2026-09-19T12:00:00.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Researchers observed decreased **TSPAN32** expression in peripheral blood T cells from patients with B‑cell lymphoma. The study tested whether raising TSPAN32 levels would improve CAR‑T antitumor activity. - Human T cells were engineered to co‑express **TSPAN32** and a CD19‑directed CAR; these TSPAN32 CAR‑T cells were compared with CD19‑CAR alone in vitro and in vivo. - In vitro, TSPAN32 co‑expression produced a more pronounced effector phenotype and increased cytokine secretion compared with CAR alone. - In subcutaneous tumor models, CAR‑T cells co‑expressing **TSPAN32** demonstrated superior therapeutic efficacy versus CD19‑CAR T cells. - RNA‑seq profiling of TSPAN32‑high CAR‑T cells revealed activation of **IL‑2 signaling** pathways relative to controls. - Mechanistic experiments showed **TSPAN32** physically interacted with **CD25**, promoted aggregation of CD25 on the T‑cell surface, and enhanced downstream IL‑2 signal transduction. - A transgenic mouse model with endogenous overexpression of TSPAN32 in T cells showed increased resistance to subcutaneous tumor growth. - A TSPAN32‑specific antibody, FF‑37, increased TSPAN32 expression and improved CAR‑T antitumor efficacy in experimental settings. - Data supporting transcriptomic analyses are available via GEO accession GSE156728. Figures in the source illustrate TSPAN32 decline in patient T cells, in vitro effector phenotype, in vivo efficacy, RNA‑seq results, TSPAN32–CD25 complex formation, transgenic mouse data, FF‑37 effects, and a mechanistic schematic. - The authors conclude that increasing **TSPAN32** expression, either by genetic engineering or with the FF‑37 antibody, may be a strategy to enhance CAR‑T cell therapy by promoting **CD25** aggregation and amplifying **IL‑2** signaling.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41416-026-03592-x#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![British Journal of Cancer](https://media.springernature.com/full/nature-cms/uploads/product/bjc/header-76ac17391903a21e28f15ff5df31f5fa.svg) ](https://www.nature.com/bjc) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41416-026-03592-x) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/bjc/research-articles) * [ Reviews & Analysis ](https://www.nature.com/bjc/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/bjc/news-and-comment) * [ Current issue ](https://www.nature.com/bjc/current-issue) * [ Collections ](https://www.nature.com/bjc/collections) * [Follow us on X ](https://twitter.com/BrJCancer) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) * [ About the journal ](javascript:;) ## About the journal * [ Journal Information ](https://www.nature.com/bjc/journal-information) * [ Open access publishing ](https://www.nature.com/bjc/open-access) * [ About the Editors ](https://www.nature.com/bjc/editors) * [ Contact ](https://www.nature.com/bjc/contact) * [ Special Issues ](https://www.nature.com/bjc/special-issues) * [ For Advertisers ](https://www.nature.com/bjc/advertising) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Publish with us ](javascript:;) ## Publish with us * [ For Authors & Referees ](https://www.nature.com/bjc/authors-and-referees) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/bjc/open-access-funding) * [Submit manuscript ](https://mts-bjcancer.nature.com/) * [ Subscribe ](https://www.nature.com/bjc/subscribe) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41416) * [ RSS feed ](https://www.nature.com/bjc.rss) 1. [nature](https://www.nature.com/) 2. [british journal of cancer](https://www.nature.com/bjc) 3. [articles](https://www.nature.com/bjc/articles?type=article) 4. article * Article * Published: 19 September 2026 Translational Therapeutics # TSPAN32 enhances CAR-T cell potency by assembling IL-2 receptor complex and amplifying its intracellular signal transduction * [Yuanyuan Sun](https://www.nature.com/articles/s41416-026-03592-x#auth-Yuanyuan-Sun-Aff1-Aff2)[1](https://www.nature.com/articles/s41416-026-03592-x#Aff1),[2](https://www.nature.com/articles/s41416-026-03592-x#Aff2) [na1](https://www.nature.com/articles/s41416-026-03592-x#na1), * [Qiang Qiu](https://www.nature.com/articles/s41416-026-03592-x#auth-Qiang-Qiu-Aff3)[3](https://www.nature.com/articles/s41416-026-03592-x#Aff3) [na1](https://www.nature.com/articles/s41416-026-03592-x#na1), * [Bochuan Wang](https://www.nature.com/articles/s41416-026-03592-x#auth-Bochuan-Wang-Aff4)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4), * [Yunyu Feng](https://www.nature.com/articles/s41416-026-03592-x#auth-Yunyu-Feng-Aff4)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4), * [Jiaxin Wang](https://www.nature.com/articles/s41416-026-03592-x#auth-Jiaxin-Wang-Aff4)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4), * [Cong Pan](https://www.nature.com/articles/s41416-026-03592-x#auth-Cong-Pan-Aff5)[5](https://www.nature.com/articles/s41416-026-03592-x#Aff5), * [Li Zheng](https://www.nature.com/articles/s41416-026-03592-x#auth-Li-Zheng-Aff4)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4), * [Huandi Qiu](https://www.nature.com/articles/s41416-026-03592-x#auth-Huandi-Qiu-Aff1-Aff2)[1](https://www.nature.com/articles/s41416-026-03592-x#Aff1),[2](https://www.nature.com/articles/s41416-026-03592-x#Aff2), * [Wei He](https://www.nature.com/articles/s41416-026-03592-x#auth-Wei-He-Aff4)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4), * [Zhiguang Su](https://www.nature.com/articles/s41416-026-03592-x#auth-Zhiguang-Su-Aff1-Aff2)[1](https://www.nature.com/articles/s41416-026-03592-x#Aff1),[2](https://www.nature.com/articles/s41416-026-03592-x#Aff2), * [Shaoguang Li](https://www.nature.com/articles/s41416-026-03592-x#auth-Shaoguang-Li-Aff6)[6](https://www.nature.com/articles/s41416-026-03592-x#Aff6) & * … * [Yiguo Hu](https://www.nature.com/articles/s41416-026-03592-x#auth-Yiguo-Hu-Aff4) [ORCID: orcid.org/0000-0002-3973-2140](https://orcid.org/0000-0002-3973-2140)[4](https://www.nature.com/articles/s41416-026-03592-x#Aff4) Show authors [_British Journal of Cancer_](https://www.nature.com/bjc) (2026) [Cite this article](https://www.nature.com/articles/s41416-026-03592-x#citeas) [ Save article ](https://www.nature.com/articles/s41416-026-03592-x/save-research?_csrf=dxCGoimu-R1nurcWTI6v2LQAzFnyyIQ6) [ View saved research ](https://www.nature.com/saved-research) ## Abstract ### Background Chimeric antigen receptor-engineered T cells (CAR-T) have shown substantial therapeutic potential in hematologic malignancies, but further improvement in T-cell functional capacity is needed to optimize efficacy. We observed reduced TSPAN32 expression in T cells from peripheral blood of patients with B-cell lymphoma. This study aimed to investigate whether TSPAN32 enhances CAR-T cell antitumor activity and to explore the underlying mechanism. ### Methods TSPAN32 expression was assessed in T cells isolated from patients with B-cell lymphoma. T cells were engineered to co-express TSPAN32 and CD19-CAR, and their antitumor efficacy and cytokine secretion were evaluated in vitro and in subcutaneous tumor models in vivo. Gene expression profiling was performed to identify signaling pathways associated with TSPAN32 overexpression. Mechanistic studies examined the interaction between TSPAN32 and CD25 and its effect on IL-2 signaling. In addition, a transgenic mouse model with endogenous TSPAN32 overexpression and a TSPAN32-specific antibody (FF-37) were used to assess therapeutic potential. ### Results TSPAN32 expression was reduced in T cells from B-cell lymphoma patients. Co-expression of TSPAN32 with CD19-CAR significantly enhanced antitumor activity and cytokine production compared with CD19-CAR alone in vitro. In vivo, T cells engineered with both CAR and TSPAN32 showed superior therapeutic efficacy in subcutaneous tumor models. Gene expression profiling indicated increased IL-2 signaling activation in TSPAN32-high CAR-T cells. Mechanistically, TSPAN32 interacted with CD25, promoting its aggregation on the T-cell surface and enhancing IL-2 signal transduction. Endogenous TSPAN32 overexpression in transgenic mice increased resistance to subcutaneous tumor growth. Furthermore, the TSPAN32-specific antibody FF-37 increased TSPAN32 expression and improved CAR-T antitumor efficacy. ### Conclusions TSPAN32 enhances CAR-T cell antitumor function by promoting CD25 aggregation and IL-2 signaling activation. Increasing TSPAN32 expression, either through genetic engineering or the TSPAN32-specific antibody FF-37, may represent a promising strategy to improve CAR-T cell therapy. This is a preview of subscription content, [access via your institution](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03592-x) ## Access options [ Access through your institution ](https://wayf.springernature.com?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03592-x) Subscribe to this journal Receive 24 print issues and online access 251,40 € per year only 10,48 € per issue [Learn more](https://www.nature.com/bjc/subscribe) Buy this article * Purchase on SpringerLink * Instant access to the full article PDF. 39,95 € Prices may be subject to local taxes which are calculated during checkout ### Additional access options: * [Log in](https://idp.nature.com/authorize/natureuser?client_id=grover&redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41416-026-03592-x) * [Learn about institutional subscriptions](https://www.springernature.com/gp/librarians/licensing/license-options) * [Read our FAQs](https://support.nature.com/en/support/home) * [Contact customer support](https://www.springernature.com/gp/contact) **Fig. 1: TSPAN32 expression declines in cancer patient T cells.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig1_HTML.png) **Fig. 2: TSPAN32 CAR-T cells display an effector phenotype and enhance anti-tumor activity in vitro.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig2_HTML.png) **Fig. 3: TSPAN32 enhances the therapeutic effects of CAR-T cells in vivo.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig3_HTML.png) **Fig. 4: Transcriptional profiling of TSPAN32 CAR-T cells using RNA-seq analysis.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig4_HTML.png) **Fig. 5: TSPAN32 forms complex with CD25 to promote intracellular signal transduction.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig5_HTML.png) **Fig. 6: Endogenously expressing TSPAN32 in T cells prevents tumor progression in vivo.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig6_HTML.png) **Fig. 7: FF-37 antibody increases TSPAN32 expression and enhances the anti-tumor function of CAR-T cells.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig7_HTML.png) **Fig. 8: Schematic diagram of TSPAN32 enhancing CAR-T cell function mechanism.** ![](https://media.springernature.com/m312/springer-static/image/art%3A10.1038%2Fs41416-026-03592-x/MediaObjects/41416_2026_3592_Fig8_HTML.png) ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Tumour immunology](https://www.nature.com/subjects/tumour-immunology) ## Data availability . ## References 1. Morotti M, Albukhari A, Alsaadi A, Artibani M, Brenton JD, Curbishley SM, et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br J Cancer. 2021;124:1759–76. [Article](https://doi.org/10.1038%2Fs41416-021-01353-6) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33782566) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144577) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Promises%20and%20challenges%20of%20adoptive%20T-cell%20therapies%20for%20solid%20tumours&journal=Br%20J%20Cancer&doi=10.1038%2Fs41416-021-01353-6&volume=124&pages=1759-76&publication_year=2021&author=Morotti%2CM&author=Albukhari%2CA&author=Alsaadi%2CA&author=Artibani%2CM&author=Brenton%2CJD&author=Curbishley%2CSM) 2. Jiang X, Xu J, Liu M, Xing H, Wang Z, Huang L, et al. Adoptive CD8+ T cell therapy against cancer: challenges and opportunities. Cancer Lett. 2019;462:23–32. [Article](https://doi.org/10.1016%2Fj.canlet.2019.07.017) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC1MXhsFSrsb%2FP) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=31356845) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Adoptive%20CD8%2B%20T%20cell%20therapy%20against%20cancer%3A%20challenges%20and%20opportunities&journal=Cancer%20Lett&doi=10.1016%2Fj.canlet.2019.07.017&volume=462&pages=23-32&publication_year=2019&author=Jiang%2CX&author=Xu%2CJ&author=Liu%2CM&author=Xing%2CH&author=Wang%2CZ&author=Huang%2CL) 3. Paijens ST, Vledder A, de Bruyn M, Nijman HW. Tumor-infiltrating lymphocytes in the immunotherapy era. Cell Mol Immunol. 2020;18:842–59. [Article](https://doi.org/10.1038%2Fs41423-020-00565-9) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33139907) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8115290) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Tumor-infiltrating%20lymphocytes%20in%20the%20immunotherapy%20era&journal=Cell%20Mol%20Immunol&doi=10.1038%2Fs41423-020-00565-9&volume=18&pages=842-59&publication_year=2020&author=Paijens%2CST&author=Vledder%2CA&author=Bruyn%2CM&author=Nijman%2CHW) 4. Zhao, Y, Deng, J, Rao, S, Guo, S, Shen, J, Du, F, et al. Tumor infiltrating lymphocyte (TIL) therapy for solid tumor treatment: progressions and challenges. Cancers. 2022;14:4160. 5. Gong N, Sheppard NC, Billingsley MM, June CH, Mitchell MJ, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25–36. [Article](https://doi.org/10.1038%2Fs41565-020-00822-y) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3MXht1Shtr8%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=33437036) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Nanomaterials%20for%20T-cell%20cancer%20immunotherapy&journal=Nat%20Nanotechnol&doi=10.1038%2Fs41565-020-00822-y&volume=16&pages=25-36&publication_year=2021&author=Gong%2CN&author=Sheppard%2CNC&author=Billingsley%2CMM&author=June%2CCH&author=Mitchell%2CMJ) 6. Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, et al. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol. 2020;38:448–59. [Article](https://doi.org/10.1038%2Fs41587-019-0398-2) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXislCjtL0%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32015548) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466194) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Interleukin-23%20engineering%20improves%20CAR%20T%20cell%20function%20in%20solid%20tumors&journal=Nat%20Biotechnol&doi=10.1038%2Fs41587-019-0398-2&volume=38&pages=448-59&publication_year=2020&author=Ma%2CX&author=Shou%2CP&author=Smith%2CC&author=Chen%2CY&author=Du%2CH&author=Sun%2CC) 7. Watanabe N, Mo F, McKenna MK. Impact of manufacturing procedures on CAR T cell functionality. Front Immunol 2022;13:876339. 8. Zhang DKY, Adu-Berchie K, Iyer S, Liu Y, Cieri N, Brockman JM, et al. Enhancing CAR-T cell functionality in a patient-specific manner. Nat Commun 2023;14(1):506. 9. Kouro, T, Himuro, H, Sasada, T Exhaustion of CAR T cells: potential causes and solutions. J Transl Med 2022;20:239. 10. Dolina JS, Van Braeckel-Budimir N, Thomas GD, Salek-Ardakani S. CD8+ T cell exhaustion in cancer. Front Immunol. 2021;12:715234. 11. Philip M, Schietinger A. CD8+ T cell differentiation and dysfunction in cancer. Nat Rev Immunol. 2021;22:209–23. [Article](https://doi.org/10.1038%2Fs41577-021-00574-3) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=34253904) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792152) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=CD8%2B%20T%20cell%20differentiation%20and%20dysfunction%20in%20cancer&journal=Nat%20Rev%20Immunol&doi=10.1038%2Fs41577-021-00574-3&volume=22&pages=209-23&publication_year=2021&author=Philip%2CM&author=Schietinger%2CA) 12. Catakovic K, Klieser E, Neureiter D, Geisberger R. T cell exhaustion: from pathophysiological basics to tumor immunotherapy. Cell Communication and Signaling. 2017;15:1. 13. Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T Cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17. 14. Zhu X, Li Q, Zhu X. Mechanisms of CAR T cell exhaustion and current counteraction strategies. Front Cell Dev Biol. 2022;10:1034257. 15. Espie D, Donnadieu E. New insights into CAR T cell-mediated killing of tumor cells. Front Immunol. 2022;13:1016208. 16. Safarzadeh Kozani P, Safarzadeh Kozani P, Ahmadi Najafabadi M, Yousefi F, Mirarefin SMJ, Rahbarizadeh F. Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero? Front Immunol. 2022;13:795164. 17. Che Y, Yang Y, Suo J, An Y, Wang X. Induction of systemic immune responses and reversion of immunosuppression in the tumor microenvironment by a therapeutic vaccine for cervical cancer. Cancer Immunol Immunother. 2020;69:2651–64. [Article](https://link.springer.com/doi/10.1007/s00262-020-02651-3) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BB3cXht12itbrP) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=32607768) [PubMed Central](http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11027467) [ Google Scholar](http://scholar.google.com/scholar_lookup?&title=Induction%20of%20systemic%20immune%20responses%20and%20reversion%20of%20immunosuppression%20in%20the%20tumor%20microenvironment%20by%20a%20therapeutic%20vaccine%20for%20cervical%20cancer&journal=Cancer%20Immunol%20Immunother&doi=10.1007%2Fs00262-020-02651-3&volume=69&pages=2651-64&publication_year=2020&author=Che%2CY&author=Yang%2CY&author=Suo%2CJ&author=An%2CY&author=Wang%2CX) 18. Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70. [Article](https://doi.org/10.1016%2Fj.oraloncology.2016.05.002) [CAS](https://www.nature.com/articles/cas-redirect/1:CAS:528:DC%2BC28XotFOgt7g%3D) [PubMed](http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Abstract&list_uids=27215705) [PubMed Central](http://www.n
## Related Clinical Research

- [Blood test trends versus single abnormal results to detect cancer in patients with unexpected weig](https://medichelpline.com/clinical-feed/plos-medicine-1-blood-test-trend-versus-single-threshold-abnormality-to-discriminate-cancer.md)
- [Erianin and Doxorubicin in Diffuse Large B-Cell Lymphoma: Study Overview on GSDMD, PI3K/AKT, and S](https://medichelpline.com/clinical-feed/pubmed-40830921.md) (DOI: 10.1097/CM9.0000000000003634)
- [Mosunetuzumab Followed by Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indol](https://medichelpline.com/clinical-feed/pubmed-42600120.md) (DOI: 10.1200/JCO-25-02906)
- [Pan-B-Lineage Control of Antigen-Heterogeneous Lymphoma Using Adapter CAR-T Cells](https://medichelpline.com/clinical-feed/biorxiv-1-pan-b-lineage-targeting-with-adapter-car-t-cells-controls-antigen-heterogeneous.md)
- [Childbirth Rates Among Female Cancer Survivors in Taiwan: Nationwide Population Study](https://medichelpline.com/clinical-feed/plos-one-0-rates-of-childbirth-in-female-cancer-survivors-a-population-based-study-in.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.